Compare AstraZeneca plc (AZN) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs QUALCOMM, Inc. — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while QUALCOMM, Inc. trades at $164.07 (market cap $170.28B). The key difference: AstraZeneca plc is the larger of the two by market cap, and QUALCOMM, Inc. pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| AZN | QCOM | |
|---|---|---|
Market Cap | $250.84B | $170.28B |
Sector | Health | Technology |
52-Week High | $209.48 | $251.10 |
52-Week Low | $147.06 | $124.07 |
Enterprise Value | $278.12B | $177.24B |
Dividend Yield | 1.97% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Qualcomm (QCOM) trades at $162.68, down 3.09% amid broader semiconductor sector pressure. The stock shows mixed signals with bearish technical indicators but strong fundamentals including recent earnings beats and a 21.01% net income margin. Recent news highlights Qualcomm's strategic pivot toward AI and data centers, though competition from Nvidia's new PC chip has sparked investor concerns. The company maintains solid cash flow generation of $14.01B from operations in 2025 and continues dividend payments.
Qualcomm presents a compelling value opportunity with a P/E of 18.53 below sector averages, supported by analyst consensus price target of $200.56 implying 23% upside. Key risks include smartphone market softness and intensifying AI competition. The company's diversification into automotive and data centers provides growth catalysts, though execution risks remain. Current levels offer attractive entry for long-term investors seeking exposure to semiconductor and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
